Evidence map›Paper›PMID 29601644›Full record

ReviewAlimentary pharmacology & therapeutics2018

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.

M T Tang, M E Keir, R Erickson, E G Stefanich, F K Fuh, T Ramirez-Montagut, J M McBride, D M Danilenko

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Alimentary pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Meta-analysis of etrolizumabTherapeutic advances in gastroenterology · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

M T TangResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.ORCID 0000-0002-4787-742X
M E KeirResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.
R EricksonResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.
E G StefanichResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.
F K FuhResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.
T Ramirez-MontagutResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.
J M McBrideResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.
D M DanilenkoResearch and Early Development, Genentech, Inc., South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel treatments with superior benefit-risk profiles are needed to improve the long-term prognosis of patients with inflammatory bowel disease (IBD). Etrolizumab-a monoclonal antibody that specifically targets β7 integrins-is currently under phase III clinical evaluation in IBD.

aimThis review summarises the available pharmacological and pharmacokinetic/pharmacodynamic data for etrolizumab to provide a comprehensive understanding of its mechanism of action (MOA) and pharmacological effects.

methodsPublished and internal unpublished data from nonclinical and clinical studies with etrolizumab are reviewed.

resultsEtrolizumab exerts its effect via a unique dual MOA that inhibits both leucocyte trafficking to the intestinal mucosa and retention within the intestinal epithelial layer. The gut-selectivity of etrolizumab results from its specific targeting of the β7 subunit of α4β7 and αEβ7 integrins. Etrolizumab does not bind to α4β1 integrin, which mediates lymphocyte trafficking to tissues including the central nervous system, a characteristic underlying its favourable safety with regard to progressive multifocal leucoencephalopathy. Phase I/II studies in patients with ulcerative colitis (UC) showed linear pharmacokinetics when etrolizumab was administered subcutaneously at 100 mg or higher once every 4 weeks. This dose was sufficient to enable full β7 receptor occupancy in both blood and intestinal tissues of patients with moderate to severe UC. The phase II study results also suggested that patients with elevated intestinal expression of αE integrin may have an increased likelihood of clinical remission in response to etrolizumab treatment.

conclusionEtrolizumab is a gut-selective, anti-β7 integrin monoclonal antibody that may have therapeutic potential for the treatment of IBD.

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedClinical Trials as TopicColitis, UlcerativeDrug Evaluation, PreclinicalGastrointestinal AgentsHumansInflammatory Bowel DiseasesIntegrin beta ChainsIntestinal MucosaAntibodies, Monoclonal, HumanizedetrolizumabGastrointestinal Agentsintegrin beta7Integrin beta Chains

Identifiers

PMID29601644
PMCPMC6001693
OpenAlexW2794448736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.